Results from the phase 2 RESONATE™-17 trial: Efficacy and safety of Ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with Del17p

被引：0

作者：

Stilgenbauer, S. ^{[1
]}

Jones, J. A. ^{[2
]}

Coutre, S. E. ^{[3
]}

Mato, A. R. ^{[4
]}

Hillmen, P. ^{[5
]}

Tam, C. ^{[6
]}

Osterborg, A. ^{[7
]}

Siddiqi, T. ^{[8
]}

Thirman, M. J. ^{[9
]}

Furman, R. R. ^{[10
]}

Ilhan, O. ^{[11
]}

Keating, M. ^{[12
]}

Call, T. G. ^{[13
]}

Brown, J. R. ^{[14
]}

Stevens-Brogan, M. ^{[15
]}

Li, Y. ^{[15
]}

Clow, F. ^{[15
]}

James, D. F. ^{[15
]}

Chu, A. D. ^{[15
]}

Hallek, M. ^{[16
,17
]}

O'Brien, S. ^{[12
]}

机构：

[1] Univ Ulm, D-89069 Ulm, Germany

[2] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA

[3] Stanford Univ, Sch Med, Div Hematol, Stanford Canc Ctr, Stanford, CA 94305 USA

[4] Hackensack Univ, Med Ctr, Hackensack, NJ USA

[5] Leeds Teaching Hosp, St James Inst Onco, Leeds, W Yorkshire, England

[6] Peter MacCallum Canc Ctr, East Melbourne, Australia

[7] Karolinska Univ Hosp Solna, Dept Hematol, Solna, Sweden

[8] City Hope Natl Med Ctr, Dept Hematol Hematopoiet Cell Transplantat, Duarte, CA 91010 USA

[9] Univ Chicago Med, Hematol Oncol Sect, Chicago, IL USA

[10] Weill Cornell Med Coll, Div Hematol Oncol, New York, NY USA

[11] Ankara Univ, Fac Med, TR-06100 Ankara, Turkey

[12] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA

[13] Mayo Clin, Div Hematol, Rochester, MN USA

[14] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA

[15] Pharmacyclics Inc, Sunnyvale, CA USA

[16] Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[17] Ctr Integrated Oncol Cologne Bonn, Cologne, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2015年 / 38卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

V291

引用

页码：92 / 92

页数：1

共 50 条

[41] Characteristics and Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Receiving Ibrutinib for ≥5 Years in the RESONATE-2 Study
Woyach, Jennifer A.
Barr, Paul M.
Kipps, Thomas J.
Barrientos, Jacqueline C.
Ahn, Inhye E.
Ghia, Paolo
Girardi, Vincent
Hsu, Emily
Jermain, Mandy
Burger, Jan A.
CANCERS, 2023, 15 (02)
[42] Final 5-Year Updated Results From a Phase 3 Study (HELIOS) of Ibrutinib Plus Bendamustine and Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (11) : 17 - 19
[43] Safety and Efficacy of the Combination of Ibrutinib and Nivolumab in Patients with Relapsed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia
Younes, Anas
Brody, Joshua
Carpio, Cecilia
Lopez-Guillermo, Armando
Ben-Yehuda, Dina
Ferhanoglu, A. Burhan
Nagler, Arnon
Ozcan, Muhit
Avivi, Irit
Albareda, Francesc Bosch
Barrigon, Maria Dolores Caballero
Masood, Aisha
Streit, Michael
Alvarez, John
Ceulemans, Rob
Masouleh, Behzad Kharabi
Balasubramanian, Sriram
Schaffer, Michael
Wang, Shean-Sheng
Fourneau, Nele
Jurczak, Wojciech
BLOOD, 2017, 130
[44] Efficacy and Safety of Zanubrutinib in Patients with Treatment-Naive Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial
Tam, Constantine S.
Robak, Tadeusz
Ghia, Paolo
Kahl, Brad S.
Walker, Patricia
Janowski, Wojciech
Simpson, David
Shadman, Mazyar
Ganly, Peter S.
Laurenti, Luca
Opat, Stephen
Tani, Monica
Ciepluch, Hanna
Verner, Emma
Simkovic, Martin
Osterborg, Anders
Trneny, Marek
Tedeschi, Alessandra
Paik, Jason
Marimpietri, Carol
Feng, Shibao
Huang, Jane
Hillmen, Peter
Brown, Jennifer R.
BLOOD, 2019, 134
[45] Updated Efficacy and Safety from the Phase 3 Resonate-2 Study: Ibrutinib As First-Line Treatment Option in Patients 65 Years and Older with Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
Barr, Paul
Robak, Tadeusz
Owen, Carolyn J.
Tedeschi, Alessandra
Bairey, Osnat
Bartlett, Nancy L.
Burger, Jan
Hillmen, Peter
Coutre, Steven
Devereux, Stephen
Grosicki, Sebastian
McCarthy, Helen
Li, Jianyong
Simpson, David
Offner, Fritz
Moreno, Carol
Zhou, Cathy
Styles, Lori
James, Danelle F.
Kipps, Thomas J.
Ghia, Paolo
BLOOD, 2016, 128 (22)
[46] Orelabrutinib Monotherapy in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Updated Long Term Results of Phase II Study
Xu, Wei
Song, Yongping
Wang, Tingyu
Yang, Shenmiao
Liu, Lihong
Hu, Yu
Zhang, Wei
Zhou, Jianfeng
Gao, Sujun
Ding, Kaiyang
Zhang, Huilai
Zhu, Zunmin
Wang, Shunqing
Xu, Bing
Hu, Jianda
Liu, Ting
Ji, Chunyan
Xia, Zhongjun
Li, Yan
Wang, Xin
Bin Zhang
Zhao, Renbin
Li, Jianyong
BLOOD, 2021, 138
[47] Updated Efficacy and Safety From the Phase 3 RESONATE-2 Study: Ibrutinib as First-Line Treatment Option in Patients 65 Years and Older With Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia
不详
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (12) : 16 - 17
[48] Alpine: Phase 3 Trial of Zanubrutinib (BGB-3111) Vs Ibrutinib in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Hillmen, Peter
Brown, Jennifer R.
Byrd, John C.
Eichhorst, Barbara F.
Lamanna, Nicole
O'Brien, Susan M.
Qiu, Lugui
Salmi, Tommi
Hilger, James
Huang, Jane
Tam, Constantine S.
BLOOD, 2019, 134
[49] Phase 2 study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia
Rogers, Kerry
Thompson, Philip
Allan, John
Coleman, Morton
Sharman, Jeff
Cheson, Bruce D.
Izumi, Raquel
Frigault, Melanie M.
Quah, Cheng
Raman, Rakesh K.
Wang, Min Hui
Kipps, Thomas J.
LEUKEMIA & LYMPHOMA, 2020, 61 : 4 - 5
[50] Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia
O'Brien, Susan M.
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (07) : 22 - 23

← 1 2 3 4 5 →